Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
3
Neutral
9
Bullish
2
Bearish
4
Neutral
9
Bullish
33
Bearish
1
Neutral
0
Bullish
31
Discovery themes featuring this stock
Glenmark Pharmaceuticals Limited is actively involved in the development, manufacture, and marketing of pharmaceutical products, focusing on formulations and active pharmaceutical ingredients. Its core areas include oncology, respiratory, and dermatology, serving major global markets.
The company’s Q3 FY26 results emphasize a consolidated revenue surge of 15.1% YoY, underscoring its robust execution across international markets, particularly India, which saw 22.1% growth buoyed by strong performance in dermatology and respiratory therapies.
Glenmark’s diverse and innovative pipeline is scaling globally, exemplified by substantial launches such as RYALTRIS and WINLEVI, which are experiencing strong uptake in Europe, the UK, and planned introductions in new markets, projecting future growth.
Strategic international partnerships, particularly in North America, boost Glenmark’s market capabilities, as highlighted by their new injectable product launches and ANDA filings, alongside regulatory successes supporting their expansion narratives.
Glenmark anticipates continued strength from their current momentum, underscored by regulatory progress in Monroe, North America, and innovative product introductions that drive their transformation into a more innovation-led entity.
Pharmaceuticals & Biotechnology
Pharmaceuticals
67,876 Cr
Low Risk
63.7
35.0
0.4
7.1
2,297.20
1,336.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Upcoming Result Date: May 28, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Glenmark Pharmaceuticals Ltd (GLENMARK) is currently trading at 2,376.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Glenmark Pharmaceuticals Limited is actively involved in the development, manufacture, and marketing of pharmaceutical products, focusing on formulations and active pharmaceutical ingredients. Its core areas include oncology, respiratory, and dermatology, serving major global markets. The company’s Q3 FY26 results emphasize a consolidated revenue surge of 15.1% YoY, underscoring its robust execution across international markets, particularly India, which saw 22.1% growth buoyed by strong performance in dermatology and respiratory therapies. Glenmark’s diverse and innovative pipeline is scaling globally, exemplified by substantial launches such as RYALTRIS and WINLEVI, which are experiencing strong uptake in Europe, the UK, and planned introductions in new markets, projecting future growth. Strategic international partnerships, particularly in North America, boost Glenmark’s market capabilities, as highlighted by their new injectable product launches and ANDA filings, alongside regulatory successes supporting their expansion narratives. Glenmark anticipates continued strength from their current momentum, underscored by regulatory progress in Monroe, North America, and innovative product introductions that drive their transformation into a more innovation-led entity.
Over the past 52 weeks, Glenmark Pharmaceuticals Ltd has traded between a low of ₹1,336.95 and a high of ₹2,297.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Glenmark Pharmaceuticals Ltd has a market capitalization of approximately 67,876.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Glenmark Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 63.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 67,876.35 Cr, Glenmark Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Glenmark Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Glenmark Pharmaceuticals Ltd is 63.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The U.S. administration announced a 100% tariff on imported branded and patented pharmaceutical drugs, scheduled to begin on October 1, 2025.
GLIPIQ is a generic version of the anti-diabetes and obesity drug semaglutide. It was launched in India by Glenmark Pharmaceuticals in March 2026, following the expiration of the drug's patent.
Semaglutide is a GLP-1 receptor agonist, a class of medication used to treat Type 2 diabetes and obesity. It works by helping the body regulate blood sugar levels and reducing appetite, leading to better glycemic control and weight loss.
It is an exclusive licensing agreement for Glenmark's experimental cancer drug, ISB 2001. AbbVie gains commercialization rights for major markets, and Glenmark's subsidiary will receive up to $1.925 billion plus royalties.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1415.00 | 87,861 Cr | 25.20 | 2.51 | 0.00 | 9.77 | 12.69 | 6.63 | ||
1129.60 | 72,611 Cr | 81.70 | 13.70 | 0.09 | 16.77 | 16.14 | 8.47 | ||
350.55 | 69,367 Cr | 179.89 | 2.04 | 0.12 | 1.14 | 3.64 | 0.58 | ||
2161.50 | 67,876 Cr | 63.73 | 7.08 | 0.10 | 26.24 | 30.84 | 5.60 | ||
5605.20 | 65,369 Cr | 27.57 | 4.90 | 0.82 | 17.69 | 18.13 | 11.95 | ||
26880.00 | 59,063 Cr | 38.06 | 12.37 | 1.71 | 32.51 | 42.54 | 23.87 | ||
1439.00 | 41,973 Cr | 46.13 | 5.65 | 0.24 | 13.33 | 17.89 | 7.73 | ||
| Median: 7 Co. | — | 1439.00 | 67,876 Cr | 46.13 | 5.65 | 0.12 | 16.77 | 17.89 | 7.73 |
Pipeline Update
Ichnos Glenmark Innovation (IGI) announced ISB 2301, a first‑in‑class multispecific antibody that targets three tumor‑associated antigens and engages T and NK cells; IND filing planned this year, with clinical studies targeted for 2027.
Results & Dividend
Glenmark Pharmaceuticals will hold a Board meeting on May 29, 2026 to consider and approve standalone and consolidated audited financial results for the quarter and year ended March 31, 2026 and to consider recommending a dividend; trading window closed Mar 31–May 31, 2026.
Board Meeting
Glenmark will hold a Board meeting on May 29, 2026 to consider and approve standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider/recommend a dividend; trading window closed Mar 31–May 31, 2026.
Product Launch
Glenmark Pharmaceuticals Inc., USA launched Vancomycin Hydrochloride for Injection USP (500 mg and 1 g vials) in the U.S.; product is bioequivalent to the Fresenius Kabi reference and the 12‑month market is ~$37.9M (IQVIA Mar 2026).
US product launch
Glenmark Pharmaceuticals Inc., USA launched Vancomycin Hydrochloride for Injection USP (500 mg and 1 g vials), bioequivalent to the Fresenius Kabi RLD, addressing a market with ~ $37.9M annual sales (IQVIA, Mar 2026).
